MedTrace Logo

A Study of SH009 Injection in Patients With Advanced Solid Tumors.

NCT07390838 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-02-05

No results posted yet for this study

Summary

Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors

Conditions

  • Liver Cancer (Locally Advanced or Metastatic)
  • Lung Cancer (NSCLC)
  • Head and Neck Cancer Squamous Cell Carcinoma
  • Breast Cancer (Locally Advanced or Metastatic)
  • Esophageal Cancer
  • Gastric Cancer (GC)
  • Solid Tumor Malignancies

Interventions

DRUG

SH009

The dosage of SH009 is 40 mg/kg QW with a treatment cycle of 28 days

Sponsors & Collaborators

  • Nanjing Sanhome Pharmaceutical, Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-16
Primary Completion
2026-12-30
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07390838 on ClinicalTrials.gov